Cadrenal Therapeutics, Inc. Common Stock (CVKD) Earnings History
Net Loss4 years of earnings data (2022–2025) · Currently unprofitable on a TTM basis
Loading earnings history...
Cadrenal Therapeutics, Inc. Common Stock (CVKD) Earnings Overview
As of June 29, 2026, Cadrenal Therapeutics, Inc. Common Stock (CVKD) reported trailing twelve-month net income of -$12M, reflecting +23.9% year-over-year growth. The company earned $-4.94 per diluted share over the past four quarters.
Looking at the long-term picture, CVKD's historical earnings data spans multiple years. The company achieved its highest annual net income of -$7M in fiscal 2022.
Cadrenal Therapeutics, Inc. Common Stock is currently reporting a net loss, though operating performance should be evaluated in the context of growth investments and industry dynamics View revenue history →
Compared to peers including PTGX (-$115M net income, -282.8% margin), TCRX (-$124M net income, -1256.8% margin), NKTR (-$158M net income, -297.1% margin), CVKD has comparable earnings metrics. Compare CVKD vs PTGX →
CVKD Earnings vs Peers
Earnings metrics vs comparable public companies
CVKD Historical Earnings Data (2022–2025)
4 years| Fiscal Year | Net Income | YoY % | Operating Income | EPS (Diluted) | Net Margin | Op. Margin |
|---|---|---|---|---|---|---|
| 2025 | -$13M | -24.3% | -$13M | $-6.64 | - | - |
| 2024 | -$11M | -27.5% | -$11M | $-8.73 | - | - |
| 2023 | -$8M | -24.5% | -$8M | $-9.63 | - | - |
| 2022 | -$7M | - | -$3M | $-8.66 | - | - |
Download Data
Export CVKD earnings history in CSV or JSON format
Free sign-in required to download data
Intrinsic Valuation
DCF models, multiple analysis, and analyst estimates.
Historical Returns
4+ years return with dividends reinvested.
DCA Calculator
See how regular investing compounds over time.
Peer Comparison
Compare growth, multiples, and margins vs sector.
CVKD — Frequently Asked Questions
Quick answers to the most common questions about buying CVKD stock.
What is CVKD earnings per share (EPS)?
CVKD trailing twelve-month (TTM) diluted EPS is $-4.94, reflecting +23.9% year-over-year growth. The 5-year EPS CAGR is N/A. Complete EPS history from 2022 to 2025 is available in the table on this page.
What is Cadrenal Therapeutics, Inc. Common Stock's net income?
Cadrenal Therapeutics, Inc. Common Stock (CVKD) trailing twelve-month net income is $-12M as of 2025. Earnings grew +23.9% year-over-year.
Is CVKD profitable?
CVKD is not currently profitable on a TTM basis, reporting a net loss of $-12M. Net margin is N/A. Investors should monitor for a return to profitability.
What is CVKD's earnings growth rate?
CVKD compound annual EPS growth rates (CAGR): 1-Year: N/A, 3-Year: N/A, 5-Year: N/A, 10-Year: N/A. These figures measure the annualised rate of diluted EPS growth over each period, based on data from 2022 to 2025.
What are CVKD's profit margins?
Cadrenal Therapeutics, Inc. Common Stock net profit margin is N/A, operating margin is N/A, and gross margin is N/A. Below-average margins reflect competitive or cost pressures. Return on Equity is -260.1%.
Is CVKD growing earnings?
Yes, CVKD earnings are accelerating — EPS growth of +23.9% exceeds the 5-year CAGR of N/A. TTM net income reached $-12M. Earnings momentum is strengthening.
What was CVKD's best earnings year?
Cadrenal Therapeutics, Inc. Common Stock's highest annual net income on record is $-7M, achieved in fiscal year 2022. Earnings history on this page spans 2022 to 2025 and includes all annual and quarterly figures.
What were CVKD's earnings last quarter?
CVKD's most recent reported quarter was Q1 2026. Net income was $-2M with diluted EPS of $-1.04. For a full breakdown of all quarters, see the quarterly earnings table on this page.